ALBI Grade (Liver)ASTCT Grading ATA Thyroid Risk BCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPI CML ELTS Score CNS-IPI CTCAE v5.0 Calvert Formula DIPSS-Plus (Myelofibrosis)Deauville Score EAU NMIBC Risk ECOG Performance Status ELN 2022 Risk (AML)ELN CML Milestones FIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2 Fleischner 2017 Guidelines Fong Clinical Risk Score HCT-CI (Sorror Score)HPV/p16 Oropharynx IGCCCG Risk (Testicular)IMDC (Heng) Criteria IMWG Myeloma Frailty IPSS-M (Molecular MDS)ISUP Grade Groups Karnofsky Status (KPS)Khorana Score Lugano Classification Lung-RADS v2022 MIPI-b (Biological)MRD Assessment Framework MSI/MMR Interpretation Mayo 20/2/20 (SMM)NCCN Prostate Risk NCCN-IPI (DLBCL)NSCLC GPA Oncotype DX Recurrence Opioid Equianalgesic PD-L1 TPS Interpretation PERCIST 2.0 PREDICT v3.0 Platinum-Free Interval R2-ISS (Revised 2)RANO 2.0 RCB (Residual Cancer Burden)RECIST 1.1 ROMA Score SAVER Score SINS Score SLiM-CRAB Criteria Sedlis/Peters Criteria TNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AML Z0011 Eligibility iRECIST iwCLL 2018 Response mRECIST (HCC)mRENAL Score mrTRG (Rectal MRI)

Recent Journal Updates

Intensive Care MedicineJun 8, 2026

Is acute respiratory distress syndrome a preventable disease?

Clinical Context

We think this might be relevant to the clinical guidance for Lung-RADS v2022.

Intensive Care MedicineJun 8, 2026

International evidence-based recommendations for point-of-care lung ultrasound

Clinical Context

We think this might be relevant to the clinical guidance for Lung-RADS v2022.

DiabetologiaJun 5, 2026

Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this has broad domain relevance to Lung-RADS v2022.

Lung-RADS v2022

LUNG-RADSLung CT Screening Classification (v2022)

Radiologic Assessment

Select Lung-RADS Category

Screening Note

The 2022 update includes modifications to nodule size thresholds and emphasizes the importance of nodule growth rate and morphology (e.g., spiculation).

Screening Outcome

Category 1

Management Outlook

Negative. No nodules or nodules with definitely benign features. Continue annual screening.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Exclusively for asymptomatic patients undergoing routine lung cancer screening with Low-Dose CT (LDCT).

Patients typically meet USPSTF criteria: age 50-80 years, ≥ 20 pack-year smoking history, currently smoking or quit within the past 15 years.

NOT to be used for patients presenting with symptoms (e.g., hemoptysis) or for incidental nodules found on standard CT (use Fleischner guidelines instead).

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Fleischner 2017 Guidelines or the TNM 9th Ed (NSCLC) to formulate a comprehensive care plan.

Last Comprehensive Review: 2026